Results 121 to 130 of about 51,615 (305)

The wolf of hypomethylating agent failure: what comes next?

Haematologica, 2019
Anne Sophie Kubasch, Uwe Platzbecker
doaj   +1 more source

Erythema Nodosum Associated with Myelodysplastic Syndrome: A Case Report [PDF]

, 2011
Adam, Christian, Langer, Alexandra, Oduncu, Fuat S., Then, Cornelia   +3 more
core   +1 more source

Oral mucosal manifestations with identical mutations to the bone marrow in a patient with VEXAS syndrome

Rheumatology &Autoimmunity, EarlyView.
Lilian Vasaitis, Lena Blomstrand, Tatjana Pandzic, Miklos Gulyas, Panagiotis Baliakas, Viktor Ljungström   +5 more
wiley   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, EarlyView.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source

Regulation of R‐Loop Dynamics by Proteins and Long Noncoding RNAs: An Emerging Paradigm for Cancer Treatment

Cancer Science, EarlyView.
R‐loops are three‐stranded nucleic acid structures whose dysregulation leads to genomic instability and cancer progression. This review summarizes the protein and lncRNA machineries that regulate R‐loop dynamics and discusses the therapeutic potential of targeting these pathways in cancer.
Miho M. Suzuki, Keiko Shinjo, Tatsunori Nishimura, Yutaka Kondo   +3 more
wiley   +1 more source

Impact of Achieving Progression‐Free Survival 24 on Subsequent Overall Survival in Diffuse Large B‐Cell Lymphoma Patients

Cancer Science, EarlyView.
The OS for patients after achieving PFS24 or PFS60 was not markedly different from that of the age‐, sex‐, and calendar period‐matched Japanese general population (PFS24: standardized mortality ratio [SMR] 1.29, 95% confidence interval [CI] 0.72–2.12, p = 0.39; PFS60: SMR 1.43, 95% CI 0.47–3.33, p = 0.55).
Ayumi Fujimoto, Wataru Munakata, Gakuto Ogawa, Ryunosuke Machida, Tomotaka Suzuki, Kazuyuki Shimada, Tsutomu Kobayashi, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Dai Maruyama, Hirokazu Nagai   +11 more
wiley   +1 more source

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [PDF]

, 2016
et al,, Fronick, C. C., Fulton, R. S., Ley, T. J., Miller, C. A., O\u27Laughlin, M., Petti, A. A., Wartman, L. D., Wilson, R. K.   +8 more
core   +2 more sources

Position statement from the British Society of Blood and Marrow Transplantation and Cellular Therapy on insertional oncogenesis in gene‐engineered advanced cell therapy products for treatment of haematological disorders

British Journal of Haematology, EarlyView.
S. Ghorashian, R. Sanderson, J. Lee, A. Black, M. A. O'Reilly, D. I. Marks, J. Snowden, D. Richardson, E. Olavarria   +8 more
wiley   +1 more source

Homoharringtonine Promotes FTO Degradation to Suppress LILRB4‐Mediated Immune Evasion in Acute Monocytic Leukaemia

Cell Proliferation, EarlyView.
Homoharringtonine (HHT) suppresses immune evasion in acute monocytic leukaemia (AML‐M5) by attenuating the FTO/m6A/LILRB4 axis, thereby enhancing CD8+ T cell cytotoxicity. ABSTRACT Acute monocytic leukaemia, a subtype of acute myeloid leukaemia (AML), is a highly aggressive malignancy characterised by a poor prognosis, primarily due to the ability of ...
Fangfang Huang, Xiang Luo, Mengyu Zhang, Le Jin, Wenxin Sun, Peihan Chen, Xiuli Hong, Chenyu Xu, Meizhi Jiang, Die Hu, Bin Zhang, Shengwei Hu, Chuanjiang Yang, Rui Gao, Jinzhang Zeng, Quanyi Lu, Qiang Luo, Jun Wu, Siming Chen   +18 more
wiley   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

European Journal of Haematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot, Frederic Baleydier, Laure Pittet, Geraldine Blanchard‐Rohner   +3 more
wiley   +1 more source